Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus

NCT00484198 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00484198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00484198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2007
Completion date
February 12, 2009
Enrollment
1,912 (actual)
Sites
183

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus